Semaglutide is used for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an add-on to the ...

March 17 (Reuters) - Indian drugmakers Zydus Lifesciences and Lupin have signed a licensing and supply deal on Tuesday to co‑market semaglutide injections in the country ahead of the ingredient's ...

As part of the deal, Lupin will pay Zydus upfront licensing fees and milestone-based payments linked to predefined targets.

Zydus Lifesciences and Torrent Pharmaceuticals have inked a licensing and supply agreement to co-market diabetes treatment medication Semaglutide Injection in the Indian market. U ...